Skip to content

Ketamine: all studies

Page 126 of 449: studies 1,251 to 1,260 of 4,483, newest first. Back to the ketamine overview

Research

Innovative Ketamine Formulations: Enhancing Therapeutic Efficacy and Safety.

ACS Medicinal Chemistry Letters August 8, 2024 Robert B. Kargbo 1 citation

Ketamine, originally developed as an anesthetic, has shown significant potential for treating depression, chronic pain, and other conditions. However, its conventional formulations often result in side effects such as hallucinations and dizziness due to rapid spikes in blood concentration. This article explores recent patents that optimize ketamine delivery and efficacy: subcutaneous injectable...

DOI: 10.1021/acsmedchemlett.4c00330 (opens in new tab) Full text (opens in new tab) Ketamine-therapy Drug-delivery-systems Pharmaceutical-innovation Depression-treatment

REVOLUTIONIZING DEPRESSION TREATMENT: A PARADIGM SHIFT OF KETAMINE THERAPY – A SYSTEMATIC REVIEW

Asian Journal of Pharmaceutical and Clinical Research August 7, 2024 Yuvraj Kaushal, Pranav Goyal, Arshiya Sehgal

Objectives: Primary Objective: (1) The objectives of the study are as follows: assessment of the effectiveness of ketamine-based treatment in known patients of various subtypes of depression and (2) assessment of time of onset and duration along with routes of administration and safety of ketamine therapy. Secondary Objective: The objectives of the study are as follows: (1) evaluate changes in...

Non-improvement predicts subsequent non-response to repeated-dose intravenous ketamine for depression: a re-analysis of a 2-week open-label study in patients with unipolar and bipolar depression.

Translational Psychiatry August 6, 2024 Chengyu Wang, Xiaofeng Lan, Weijian Liu et al. 6 citations

There is insufficient evidence to guide dose and frequency optimization with repeated-dose ketamine for depression. This study assessed the value of symptomatic non-improvement after the first few ketamine infusions as a predictor of overall non-response in depression for early decision-making to discontinue treatment. A total of 135 individuals with major depressive disorder or bipolar...

DOI: 10.1038/s41398-024-03027-2 (opens in new tab) Full text (opens in new tab) Depression treatment Ketamine therapy Mental health research Treatment response prediction

LSD and ketamine in schizoaffective paranoid psychosis involving childhood and war trauma—a retrospective case study

August 5, 2024 Mika Turkia preprint

Currently, documentation on the effects of psychedelics on psychosis appears scarce. In the present case, a higher-dose LSD experience during acute paranoid psychosis before the initiation of antipsychotics induced feelings of love, which resolved the majority of the symptoms of the paranoid psychosis in one session, leading the person to reconnect with his family and seek treatment in a...

DOI: 10.31234/osf.io/5azpy (opens in new tab) Paranoia Psychosis Aripiprazole Antipsychotic +3

Ketamine-enhanced prolonged exposure therapy in veterans with PTSD: A randomized controlled trial protocol.

Contemporary Clinical Trials August 1, 2024 Paulo R Shiroma, Paul Thuras, Melissa A Polusny et al. 7 citations

The 2023 VA/DoD Clinical Practice Guideline for the Management of PTSD recommends individual, manualized trauma-focused such as Prolonged Exposure (PE) over pharmacologic interventions for the primary treatment of PTSD. Unfortunately, clinical trials of trauma-based therapies in the military and veteran population showed that 30% to 50% of patients did not demonstrate clinically meaningful...

DOI: 10.1016/j.cct.2024.107569 (opens in new tab) Full text (opens in new tab) Prolonged exposure PTSD-Treatment Veterans-mental-health Ketamine-therapy +2

Fluorodeschloroketamine found as a street drug in drug seizures and drug driving cases in Hong Kong.

Forensic Science International August 1, 2024 Wing-Chi Cheng, Kwok-Leung Dao, Wing-Cheong Wong 3 citations

With the decline of the use of ketamine, one of the common drugs of abuse in Hong Kong, detection of ketamine-related analogues in local laboratories has been encountered. A brief account of the occurrence of fluorodeschloroketamine (FDCK) in forensic cases is reported through a retrospective study of all drug seizures and driving under the influence of drugs (DUID) cases since its first...

DOI: 10.1016/j.forsciint.2024.112075 (opens in new tab) Full text (opens in new tab) Drug driving Drug seizures Fluorodeschloroketamine Fluorodeschloronorketamine +4

Effects of association between resveratrol and ketamine on behavioral and biochemical analysis in mice.

Journal of Neural Transmission August 1, 2024 Patrícia Zorzi Juliani, Talita Rodrigues, Getulio Nicola Bressan et al. 4 citations

Resveratrol (3,5,4'-trihydroxy-trans-stilbene), a phenol commonly found in grapes and wine, has been associated as protective in experimental models involving alterations in different neurotransmitter systems. However, studies are reporting that resveratrol could have adverse effects. This study evaluated if the association of a low dose of ketamine and resveratrol could induce behavioral...

DOI: 10.1007/s00702-024-02793-z (opens in new tab) Full text (opens in new tab) Il-6 Lipid peroxidation Locomotor activity Monoamine oxidase +6

The Use of Ketamine for the Treatment of Anhedonia in Depression.

CNS Drugs August 1, 2024 Liliana Patarroyo-Rodriguez, Stefanie Cavalcanti, Jennifer L. Vande Voort et al. 13 citations

Anhedonia, a complex symptom rooted in deficits across reward processes, is primarily linked to depression and schizophrenia but transcends diagnostic boundaries across various mental disorders. Its presence correlates with poorer clinical outcomes, including an increased risk of suicide and diminished response to treatment. The neurobiological underpinnings of anhedonia remain incompletely...

Administration of low dose intranasal ketamine exerts a neuroprotective effect on whole brain irradiation injury model in wistar rats.

Radiation and environmental biophysics August 1, 2024 Gökhan Yaprak, Nilsu Çini, Özüm Büke Atasoy et al. 3 citations

Exposure to ionizing radiation leads to oxidative stress and neuroinflammation, resulting in neurocognitive impairments. Adverse effects are also associated with glutamate-induced excitotoxicity due to alterations in the composition of glutamate receptors. Ketamine, which is a noncompetitive NMDA glutamate receptor antagonist, has been stated to exert an impact on glutamatergic receptors. This...

DOI: 10.1007/s00411-024-01085-0 (opens in new tab) Full text (opens in new tab) Bdnf Brain injury Neuroinflammation Oxidative stress +9

Can mind-altering prescription medicines be safe? Lessons from ketamine and esketamine.

Clinical Toxicology August 1, 2024 Richard C. Dart 9 citations

Recent decades have witnessed an extraordinary global crisis of drug misuse. Although opioid analgesics receive the most attention, numerous other drugs have increased rates of misuse. Ketamine and esketamine offer a unique natural experiment to explore two medications that are similar pharmacologically but differ in their availability to users and in their regulation by government agencies....